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Melatonin blocks the stimulatory effects of prolactin on human breast
cancer cell growth in culture
A Lemus-Wilson"3, PA Kelly2 and DE Blask3
'The University ofArizona, Tucson, Arizona, USA; 2INSERM Unite 344, Endocrinologie Moleculaire, Faculte de Medicine
Necker, 75730 Paris, France; 'The Bassett Research Institute, Cooperstown, New York, 13326-1394, USA.
Summary Melatonin (aMT) appears to be a potentially important oncostatic substance that can block the
mitogenic effects of tumour-promoting hormones and growth factors such as oestradiol and epidermal growth
factor, in vitro. In the present study, we examined the possibility that aMT would also inhibit the stimulatory
effects of the tumour-promoter prolactin (PRL) on MCF-7 and ZR75-1 human breast cancer cell (HBC)
growth under 5% charcoal-stripped fetal bovine serum culture conditions. Human PRL (10-100ng ml-')
stimulated the rate of MCF-7 and ZR-75-1 HBC growth up to 2-fold above that of untreated controls.
Melatonin, at concentrations between 1012-M and 10-5M, diminished and at physiological levels completely
abolished PRL's mitogenic activity, but had no effect on growth in the absence of PRL. The mitogenic effects
of human growth hormone (hGH), a PRL-related hormone, and also of several monoclonal antibodies
(MAbs) against the PRL receptor (PRLR), were also abrogated by physiological concentrations of aMT.
Additionally, aMT blocked the enhancement of MAb mitogenic activity induced by a second 'cross-linking'
antibody (CLA). These findings indicate that aMT interrupts the PRLR-mediated growth signal in HBC and
suggest that the oncostatic activity of aMT may also be linked with an antagonism of PRL's actions.
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Melatonin (aMT), the chief hormone from the pineal gland
(Reiter, 1991), appears to be an important inhibitor of cancer
(Blask, 1993). Over the past decade a considerable amount of
evidence has accumulated suggesting that aMT has potent
antineoplastic properties, particularly with respect to the
development of breast neoplasms (Blask et al., 1990, 1992).
For example, several workers have shown that exogenously
administered aMT impedes chemically induced mammary
tumorigenesis in rodents (Aubert et al., 1980; Kothari et al.,
1984; Blask et al., 1991). Moreover, the reduction of aMT in
the blood, via surgical or functional pinealectomy, enhances
carcinogenesis in susceptible animals but not those given
aMT (Tamarkin et al., 1981; Shah et al., 1984). In addition,
aMT impedes the growth of human breast cancer cells in
vitro (Hill and Blask, 1988; Shellard et al., 1989; Cos and
Blask, 1990) and breast tumours transplanted into rats (Kar-
mali et al., 1978). Since these results suggest that circulating
aMT in the blood may impart some protection against mam-
mary tumorigenesis and that established tumours retain their
sensitivity to aMT's cytostatic effects, it has been postulated
that breast cancer may respond favourably to aMT therapy
(Karmali et al., 1978). These ideas are also supported by
aMT's ability to reduce the circulating levels and/or activity
of mammogenic hormones such as oestrogen and prolactin
(PRL) (Reiter, 1980; Blask and Leadem, 1987), both of
which stimulate breast cancer growth (Welsch, 1985; Rose
and Noonan, 1989). One of the most interesting aspects of
aMT's anti-cancer activity is its ability to inhibit the growth
of the tumour cell itself by blocking the stimulatory effects of
other hormones and growth factors. For example, recent
studies have shown that aMT can inhibit human breast
cancer cell (HBC) proliferation by blocking the mitogenic
actions of both oestradiol and epidermal growth factor (Cos
et al., 1991; Hill et al., 1992; Cos and Blask, 1994), and
causing a delay at the GO/G, stage of the cell cycle (Cos et
al., 1991).
In this study, we examined aMT's potential for blocking
the mitogenic actions of PRL on HBCs grown in culture.
The examination of aMT inhibition of PRL's mitogenic
action, albeit not previously studied, is warranted, based on
aMT's ability to inhibit PRL-dependent mammary tumours
in vivo (Tamarkin et al., 1981; Shah et al., 1984; Blask et al.,
1991; Subramanian and Kothari, 1991) and on the increasing
concern that PRL promotes breast malignancies in humans
(Bonneterre et al., 1987; Shiu et al., 1987; Boutin et al., 1989)
as it does in rodents (Welsch, 1985). The effects of aMT on
PRL-stimulated HBC growth were studied in the MCF-7 and
ZR-75-1 oestrogen receptor (ER)-positive HBC models
because of the widespread use of these cells and their estab-
lished sensitivity to PRL under defined (lactogen-deficient)
serum conditions (Biswas and Vonderhaar, 1987; Vonderhaar
and Biswas, 1987; Vonderhaar, 1989).
We also tested aMT's ability to inhibit the mitogenic
activity of a PRL-related hormone, human growth hormone
(hGH), as well as the mitogenic effects of several mouse
monoclonal antibodies (MAbs) directed against the PRL
receptor (PRLR) (Kelly et al., 1988; Eldberg et al., 1990).
The MAbs were tested by themselves and also in combina-
tion with a second antibody that boosts the mitogenic actions
of the MAbs, resulting in a further increase in proliferation
(Eldberg et al., 1990). These additional studies helped clarify
aMT's anti-PRL action since both hGH (Biswas and Vonder-
haar, 1987) and the MAbs (Kelly et al., 1988) obstensibly
stimulate proliferation through the PRLR.
Materials and methods
Human breast cancer cells
Human MCF-7 breast cancer cells were obtained from Dr
Steven Hill of Tulane University (New Orleans, LA, USA),
and also from American Type Culture Collection, Rockville,
MD, USA. The ZR-75-1 breast cancer cells were purchased
from the American Type Culture Collection. All cells were
routinely tested for mycoplasma contamination and were
determined to be mycoplasma free.
Other materials and hormones
Culture media, antibiotics and trypan blue were obtained
from Gibco (Grand Island, NY, USA). Fetal bovine serum
was obtained from Gibco and Tissue Culture Biologicals
(Tulare, CA, USA). Dextran T-70 was supplied by Phar-
macia (Piscataway, NJ, USA). Melatonin was obtained from
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Sigma (St Louis, MO, USA). Human PRL (NIADDK-
hPRL-1-6, >99.9% purity) and Human GH (NIDDK-hGH-
B-1) were generous gifts from Dr Salvatore Raiti of the
National Pituitary Hormone Program. Monoclonal anti-
bodies to the PRLR were those described previously (Kelly et
al., 1988, 1989) that have been shown to cross-react with the
human PRLR (Eldberg et al., 1990). Rabbit antiserum to
mouse immunoglobulin G was purchased from Calbiochem
(La Jolla, CA, USA).
Culture techniques
MCF-7 and ZR-75-1 cells were maintained and routinely
subpassaged in Dulbecco's modified Eagle medium (DMEM)
supplemented with penicillin (200 U ml '), streptomycin
(200 jLgml-'), and 10% fetal bovine serum (FBS), at 37°C in
a humid atmosphere containing 5% carbon dioxide. Before
growth studies, cells were grown for at least 4 days in 10%
charcoal-stripped FBS (CSS) to minimise the carry-over of
bovine lactogens into the experiments.
Preparation ofcharcoal-stripped serum
A modification of the charcoal-stripping methods of Lipp-
man et al. (1976) was used in the present study. Briefly, Norit
A charcoal was repeatedly washed first with 1 M hydrogen
chloride then with phosphate-buffered saline (PBS) contain-
ing 1 mg ml-' of Dextran T-70 pH 7.2. The charcoal suspen-
sion was then dried in an oven overnight and 25 mg of
dextran-coated charcoal was added to 500 ml of FBS at 56°C
for 30 min. This suspension was then centrifuged at 10000 g
for 45 min and prefiltered through a millipore glass fibre
filter. The serum was then re-exposed to dextran-coated char-
coal for 1-2 additional cycles in order to further reduce its
lactogen content. The CSS was sterilised by passage through
a 0.22LLM millipore filter and then stored at -20°C until
needed. This procedure reduced the bovine lactogen content
of the serum by 98% (<3 ngml-') as determined by radio-
immunoassay (RIA). In addition, 83% of the endogenous
oestrogens were removed as determined by RIA.
In vitro cellgrowth studies
Cells were harvested from 70-80% confluent cultures and
reseeded onto 60 mm x 15 mm Falcon plates at a density of
3 x 105 cells/plate. DMEM supplemented with 5% lactogen-
deficient CSS and 2% antibiotics was used for the culture of
both MCF-7 and ZR-75-1 cells. After 24 h the medium was
replaced with fresh DMEM containing either vehicle, hor-
mones and/or MAbs. Melatonin was dissolved in ethanol
(EtOH) then diluted with medium to 10-12-0- M. The level
of EtOH carried over into the studies was not more than
0.035% (vehicle control). The cells were allowed to grow for
up to 6 days in this medium. Cell number for triplicate plates
for each treatment was determined with a haemocytometer
after detachment of the cells with PBS/EDTA and their
passage through a 25 gauge syringe. Cell viability (>95%)
was assessed by the trypan blue exclusion test. A mean
growth rate from triplicate plates was calculated based on
cell number. The growth rate was equal to the difference
between the initial number of cells seeded per plate and the
number of cells found at a particular time point, at any time
from 24-144 h, divided by the initial cell number. For com-
parisons between groups the mean rate of growth in each
treatment group was graphed as a per cent of control growth
rate. Unless otherwise stated the data are expressed as the
mean of three independent experiments.
For the PRL dose-response studies 20-100ngml1' of
hormone was used, the other experiments used only the
20 ng ml' dose. In the hGH dose-response studies
20-100ngml-' of hormone was used. In the MAb studies,
MAbs T1, T6, U5, U6 or E21 were each used at a final
concentration of 0.62 nM. In the experiments with the CLA,
a dilution of 1:1250 was used because it was the most
effective at enhancing the mitogenic activities of the TI and
T6 MAbs.
Statistical analysis
Mean ± (s.e.m.) growth rate for hormone-treated cells was
expressed as a per cent of the control growth rate (100%).
All data were analysed with a one-way ANOVA and statis-
tical differences among mean values were determined by
Student Newman-Keuls post hoc test. Differences between
and among means were considered significant at P<0.05.
Results
Dose-response ofHBC growth to PRL in thepresence or
absence ofaMT
As shown in Figure la and b, PRL, at concentrations rang-
ing from 20 to 100 ng ml1', significantly increased the rate of
MCF-7 and ZR-75-1 cell growth as compared with untreated
controls when cells were grown for 3 days as monolayer
cultures in medium supplemented with 5% CSS and hor-
mone. A physiological dose of PRL (20 ng ml1') caused the
greatest increase (2-fold) in both MCF-7 and ZR-75-1 cell
growth as compared with untreated control.
Melatonin (10-9M) substantially reduced the growth of
both MCF-7 and ZR-75-1 cells in the presence of increasing
doses of PRL (Figure la and b). In fact, the rate of growth
in both MCF-7 cell and ZR-75-1 cells treated concomitantly
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Figure 1 Effects of aMT on the human PRL-stimulated growth
of MCF-7 (a) and ZR-75-1 (b) human breast cancer cells. Cells
were treated with PRL at concentrations ranging from 20 to
100 ngml'l in the presence of aMT (10-9M) (0) or in the
absence of aMT (V). The growth rate was determined as des-
cribed in Materials and methods following a 3 day exposure to
hormones. The data points represent the mean (± s.e.m.) per cent
of untreated control growth rate (100%) from three separate
experiments. aMT + PRL vs PRL P<0.05 at all concentrations
of PRL.
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_with aMT (10-9M) and PRL at a dose of 20ngmlV- was
equivalent to that of controls, indicating that the stimulatory
effect of PRL on growth was completely abolished by aMT.
Even greater reductions in growth, below the levels in vehicle
controls, were seen in ZR-75-1 cells exposed for longer
periods (5-6 days) to aMT plus PRL (data not shown).
However, aMT in the absence of PRL had no effect on
growth in both MCF-7 and ZR-75-1 cells.
Temporal effects ofaMTplus PRL on HBC growth
Figure 2 shows the growth response of MCF-7 cells to PRL
(20ngml-') and/or aMT (10-9M) over a 6 day incubation
period. The highest rate of growth (2-fold greater than con-
trol) was seen in PRL-treated cells on the 3rd day of incuba-
tion. This high level of growth could be maintained through-
out the culture period by adding fresh hormone and medium
on days 2 and 4 of the experiment (not shown). Otherwise,
on days 4 and 6, PRL increased growth 1.5-fold and 1.2-fold
respectively, as compared with untreated controls (shown). In
contrast, there was no increase seen in the growth of cells
treated with PRL plus aMT throughout the incubation
period. In fact, the growth rate tended to be lower than that
of the vehicle-treated controls at each time point tested.
Again, aMT in the absence of PRL had no effect on growth
over the course of the study.
Dose-response ofHBCgrowth to aMT in the presence ofPRL
Figure 3 illustrates the response of MCF-7 cells to PRL in
the presence of increasing concentrations of aMT (10-12 M-
10- M), following a 3 day incubation period. While PRL
alone significantly increased growth (1.8-fold) as compared
with controls, the growth ofcells treated with PRL plus aMT
at concentrations between 10`0 M and 10-8 M was equal to
or less than that of untreated controls. The rate of growth
was also substantially lower (50-80% less) in cells treated
with lower concentrations of aMT (10-12 M and 10-
" M) plus
PRL as compared with growth with PRL alone. With the
exception of aMT (10-6 M), supraphysiological levels of aMT
(10-7 M-10-S M) plus PRL did not significantly alter growth
from that seen with PRL alone. Similarly, aMT by itself, at
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each of the concentrations tested, did not significantly alter
growth with the exception of the 10-6 M concentration. This
high level of aMT increased growth by an average of 50% as
compared with untreated controls (data not shown).
Dose-response ofHBC to human GH in thepresence or
absence ofaMT
The mitogenic response of MCF-7 cells to increasing concen-
trations of human GH (25-100 ngml') in the presence or
absence of aMT is shown in Figure 4. Human GH, at each
concentration tested, significantly increased growth by as
much as 80% when compared with untreated controls. How-
ever, in cells exposed simultaneously to human GH and aMT
the rate of growth was significantly less than that seen with
GH alone. In fact, the growth of cells treated with GH at
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Figure 3 Effects of increasing doses of aMT (10-I2M-I0- IM)
on the PRL (20 ng ml -)-stimulated proliferation of MCF-7 cells.
The growth rate was determined following a 3 day exposure to
hormones as described in the Materials and methods. Data point
represent the mean (± s.e.m.) per cent of untreated control
growth (100%). *P<<0.05 aMT + PRL vs PRL alone.
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Figure 2 Effects of human PRL (20 ng ml- 1) either alone (U) or
in combination with aMT (10-9 M; A) on the growth of MCF-7
cells over a 6 day incubation period. The cells were harvested on
days 2, 3, 4 and 6. V, Untreated control; *, melatonin alone.
The rate of cell growth in each treatment group was determined
as described in Materials and methods. Data points represent the
mean (± s.e.m.) per cent of the untreated control growth rate
(100%). *P<0.05 PRL alone vs aMT + PRL.
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Figure 4 Effects of increasing concentrations of human GH on
the growth of MCF-7 cells either in the presence (v) or absence
of aMT (10-9M) (V). The cells were harvested and counted
following a 3 day incubation period, as described in Materials
and methods. Data points represent the mean (± s.e.m.) per cent
of the control growth rate. *P<0.05 aMT + GH vs GH
alone.
250
0)
g 200
-W
m
200
0
CD
0
0
0)
0)
10
u I I I I
.. v
---
7
-
-
-
-
-
-
k
vI _ _ r
_ %99 7
-
_
-
_
F
I I I I
I I IIIMelatonin and prolactin in human breast cancer
r_ A Lemus-Wilson etal
1438
25 ng ml- plus aMT was reduced to the untreated control
level. In contrast, aMT in the absence of GH had no effect
on growth.
Mitogenic effects ofMAbs on HBC
Figure 5 demonstrates the mitogenic response of MCF-7 cells
to several different MAbs directed against the PRLR follow-
ing a 3 day incubation period. The growth rates of cells
treated with the MAbs TI, T6, U5, U6 or E21 (0.62 nM)
were 1.7-, 1.5-, 1.4-, 1.8- and 1.4-fold higher, respectively,
than that of the controls. Interestingly, both TI and U6
increased growth by an amount that was not significantly
different from that seen with the native ligand while a non-
specific mouse IgG had no effect on growth (data not
shown).
with U5, CLA plus aMT was reduced to the level observed
with U5 alone. Hence, aMT diminished the activity of the
MAbs even in the presence of CLA. Since CLA had no effect
on U6 (0.62 nM)-stimulated growth, this treatment group was
excluded from the study.
Discussion
Under the appropriate culture conditions, MCF-7 and ZR-
75-1 human breast cancer cells are sensitive to a number of
different mitogens including the pituitary hormone PRL (Bis-
was and Vonderhaar, 1987; Vonderhaar, 1989). In the pre-
sent study, we used these specific culture conditions (5%
CSS) to investigate the possibility that aMT would inhibit
Effects ofaMT on MAb-stimulated HBCgrowth
The stimulatory growth response of MCF-7 cells to TI in the
presence of aMT is depicted in Figure 6. TI (0.62 nM) in-
creased growth 1.6-fold as compared with controls. In cells
treated with aMT (10-9M) plus TI, the growth rate was
significantly less than that found in TI-treated cells and was
almost equal to that of controls. U6 (0.62 nM) also increased
growth 1.9-fold as compared with controls. However, in cells
treated with U6 plus aMT growth was significantly reduced
to almost that of controls. Monoclonal antibody U5
(0.62 nM) caused a similar enhancement of growth, but to a
lesser extent than did TI or U6. The growth rate in cells
incubated with U5 plus aMT was reduced to that of controls
as well.
Effects ofaMT on CLA-enhanced MAb-stimulated HBC
growth
Figure 7 shows the second cross-linking antibody's (CLA)
ability to enhance the activities of the MAbs TI and U5. TI
(0.62 nM) plus CLA (1:1250 dilution) increased growth 1.9-
fold as compared with untreated controls and was approx-
imately 25% greater than the rate seen with TI alone.
Similarly, U5 alone increased growth 1.4-fold as compared
with control, while U5 plus CLA increased growth 2-fold as
compared with untreated controls. This was 40% above the
level observed with U5 alone. In cells exposed simultaneously
to TI, CLA and aMT (10-9M) the rate of growth was
reduced to vehicle control levels, while growth in cells treated
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Figure 6 Effects of PRLR MAbs, TI, U6 and U5 (0.62nM)
either alone or in combination with aMT (10-9M) on MCF-7 cell
proliferation. Cells were exposed to hormone and/or antibodies
for 3 days then harvested and counted as described in Materials
and methods. The rate of cell growth in each treatment group
was expressed as the mean (± s.e.m.) per cent of the untreated
controls (CTL) (100%). *P<0.05 vs MAbs alone.
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Figure 5 Effects of PRLR MAbs, Tl, T6, U5, U6, and E21
(0.62 nM) on the proliferation of MCF-7 cells. The cells were
harvested and counted following a 3 day incubation period. The
bars represent the mean (± s.e.m.) per cent of the untreated
control (CTL) growth rate (100%). *P<0.05 MAb vs untreated
control.
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Figure 7 The effects of aMT on CLA-enhanced MAb-stimulated
MCF-7 cell proliferation. MCF-7 cells were exposed to MAb Tl
or U5 (0.62 nM) plus either CLA (rabbit IgG) (1:1250 dilution)
or CLA and aMT (10-9M) for 3 days, harvested and then
counted as described in Material and methods. Growth was
expressed as a percent of vehicle-treated control (CTL) (100%).
Bars represent the mean (± s.e.m.) of two independent
experiments. *P<0.05 vs MAb plus CLA.
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the mitogenic response of these human breast cancer cell
lines to human PRL. In addition, we tested aMT's ability to
inhibit the mitogenic activity of human GH, a homologous
mammogenic hormone which can stimulate MCF-7 cell pro-
liferation via the PRLR (Biswas and Vonderhaar, 1987).
Moreover, we tested aMT's potential ability to inhibit the
'PRL-like' activity of several different MAbs directed against
the PRLR (Kelly et al., 1988; Eldberg et al., 1990).
As anticipated on the basis of earlier studies (Biswas and
Vonderhaar, 1987; Vonderhaar and Biswas, 1987; Vonder-
haar, 1989), we found that human PRL stimulated the
growth of MCF-7 and ZR-75-1 cells under lactogen-deficient
media conditions. A physiological concentration of PRL
(20 ngmlP") elicited the best stimulation of cell growth in
both cell lines. The degree of stimulation (2-fold) was within
the range (1.5- to 3.0-fold) typically observed by us, but was
less than the maximum mitogenic response (greater than
3-fold) reported previously by Biswas and Vonderhaar
(1987). The difference in sensitivity to PRL in our study may
relate to differences in the lot of FBS used, the charcoal-
stripping process, and/or to a different clone of MCF-7 cells.
These factors may also have contributed to the failure of
some workers to observe a growth response of MCF-7 cells
to PRL (Shiu, 1981; Jozan et al., 1982; Shafie and Brooks,
1977; Kelly et al., 1989), which has been discussed in detail
elsewhere (Biswas and Vonderhaar, 1987).
When MCF-7 cells were exposed simutaneoulsy to physio-
logical levels of human PRL and aMT, the mitogenic res-
ponse to PRL was blocked at each of the time points tested.
In fact, in one instance the addition of aMT significantly
reduced the rate of cell growth below untreated control levels
indicating that PRL may actually increase MCF-7 cell sen-
sitivity to the inhibitory effects of aMT. We previously sug-
gested a similar notion to explain PRL's ability to restore
aMT's oncostatic activity under serum-free medium condi-
tions (Blask and Hill, 1986). Not surprisingly, aMT in the
absence of mitogen did not affect cell growth as compared
with untreated controls, under these culture conditions. This
finding is consistent with an earlier report that aMT depends
on serum factors for its anti-proliferative activity in MCF-7
cells (Blask and Hill, 1986).
Interestingly, concentrations of aMT that are normally
present in the blood during the night (10-" M-10-9 M)
(Reiter, 1980) suppressed PRL-stimulated growth most
effectively. Concentrations of aMT outside of this range
were, for the most part, increasingly less inhibitory. In fact,
the highest concentration of aMT tested (10-I M) was com-
pletely ineffective in inhibiting PRL-stimulated growth. Hill
and Blask (1988) observed a similar bell-shaped, dose-
dependent inhibitory response to aMT in MCF-7 cells grown
under different culture conditions. The reason for the
unusual response curve is unknown but may reflect
differential regulation of receptor and signal transduction
pathways at different concentrations of melatonin. It is
important to mention that an inhibitory growth response,
albeit highly variable, was seen at the 10-6 M concentration
of aMT. This suggests that MCF-7 cells may also be sensitive
to a narrow range of supraphysiological levels of aMT.
Corroborating the reports of Biswas and Vonderhaar
(1987), we found that human GH stimulated the proliferation
of MCF-7 cells, which is consistent with GH's reported
competitive binding to the PRLR (Murphy et al., 1984).
Melatonin substantially reduced the mitogenic response of
MCF-7 cells to human GH.
We also demonstrated a mitogenic response of MCF-7
cells to several distinct mouse MAbs directed against the
PRLR (Kelly et al., 1988). The MAbs TI and U6 were the
best stimulators of cell growth in this study. Like the native
ligand PRL, they increased the rate of growth 1.5- to 1.9-fold
as compared with untreated controls. The other MAbs tested
(T6, U5, and E21), which recognise epitopes of the PRLR
not bound by PRL, also elicited mitogenic responses from
the MCF-7 cells, but generally to a lesser extent. However, a
non-specific mouse IgG control consistently had very little or
no effect on growth, verifying the specificity of the mitogenic
response to the MAbs. The response of the MCF-7 cells to
each of the MAbs varied as was anticipated, based on differ-
ences in their PRLR binding capacities (Kelly et al., 1988;
Eldberg et al., 1990).
The MAbs used here can stimulate rat Nb2 lymphoma cell
proliferation (Eldberg et al., 1990). However, this was the
first demonstration, to our knowledge, of their biological
activity in human cancer cells.
Melatonin not only inhibited the mitogenic activities of the
MAbs, but also diminished the enhanced mitogenic response
of MCF-7 cells to the combination of MAb with an enhanc-
ing titre of CLA. The non-specific second antibody increases
the mitogenic potency of the MAbs presumably by facili-
tating PRLR dimerisation or oligomerisation, a critical step
in the PRLR signal transduction pathway (Eldberg et al.,
1990).
Interestingly, the CLA boosted the mitogenic effects of
each of the MAbs tested (T6, TI, and U5) except U6 (not
shown), which was already capable of inducing high levels of
growth. In addition, the final level of growth achieved with
each of the MAbs was equal to that seen with PRL, despite
earlier differences in their mitogenic effects. These findings
suggest that the variability in the growth responses to the
MAbs may be reflective of differences in their abilities to
induce dimerisation and not just their binding capacities. It
appears, therefore, that dimerisation or oligomerisation of
the PRLR may be crucial to PRL's biological effects on
breast cancer cells, as well as in other cell types. It is
noteworthy that the CLA may have reduced aMT's ability to
inhibit U5-stimulated growth. Thus, it is conceivable that
aMT's inhibition of PRL-stimulated MCF-7 cell growth
might involve an interference with some aspect of the PRLR
dimerisation process.
Altogether, the results shown here indicate that aMT can
attenuate the mitogenic response of human breast cancer
cells grown in vitro to the tumour-promoting hormone PRL
and also other related mitogens (e.g. human GH) that
stimulate proliferation via an interaction with the PRLR.
Furthermore, we have shown that aMT does this by inhibit-
ing the PRLR-mediated growth signal in these cells. More-
over, we observed the aMT-anti-PRL phenomenon in two
distinct HBC lines suggesting that other PRL-sensitive breast
cancer cell types may respond similarly to aMT. Thus, it
seems likely that aMT's reported antineoplastic effect on
PRL-dependent experimental mammary tumorigenesis
(Tamarkin et al., 1981; Shah et al., 1984; Blask et al., 1991,
Subramanian and Kothari, 1991) in vivo is due partly to its
ability to inhibit PRL's mitogenic actions. Moreover, our
demonstration that aMT inhibits breast cancer growth at
physiologically relevant concentrations lends additional sup-
port to the notion that aMT may be a naturally occurring
oncostatic hormone (Blask, 1993). The suppressive effect of
aMT on mammary tumour growth is reminiscent of its
inhibitory influence on mammary gland development during
puberty in other mammalian species (Sanchez-Barcello et al.,
1990, 1991). Hence, the nocturnal pineal secretion of aMT
may be part of a normal regulatory mechanism suppressing
mammary growth that persists during malignancy and is
therefore of clinical relevance.
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